NEW YORK, Feb. 5 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will be presenting at the following upcoming Investor Conferences:
Thursday, February 7th, 2008 - 10:20 AM ET:
Merrill Lynch 19th Global Pharmaceutical, Biotechnology & Medical
Grand Hyatt Hotel
New York City
Monday, February 11, 2008 - 12:30 PM ET:
BIO CEO & Investor Conference
New York City
Each of Mr. Weiss' presentations will be webcast live and may be accessed from the Investor Information page of the Company's Website at http://investors.keryx.com. An archived version of each presentation webcast will be available following the conclusion of the live presentation.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, Inc. is focused on the acquisition,
development and commercialization of medically important, novel
pharmaceutical products for the treatment of life-threatening diseases,
including diabetes and cancer. Keryx's lead compound under development is
Sulonex(TM) (sulodexide oral gelcap), previously referred to as KRX-101, a
first-in-class, oral heparinoid compound for the treatment of diabetic
nephropathy, a life-threatening kidney disease caused by diabetes. Sulonex
is in a pivotal Phase 3 and Phase 4 clinical program under a Special
Protocol Assessment with the Food & Drug Administration. Additionally,
Keryx is developing Zerenex(TM), an oral, iron- based compound that has the
capacity to bind phosphate and form non-absorbable complexes. Zerenex is
currently in Phase 2 clinical development for the treatment of
hyperphosphatemia (elevated serum phosphorous levels) in patients with
end-stage renal disease. Keryx is also developing clinical-stage oncology
compounds, including KRX-0401, a novel, first-in-class, oral anti-cancer
agent that modulates Akt, a protein in the body associated with tumor
survival and growth, and a number of other key signal transduction
pathways, including the JNK and MAPK pathways, which are pathways
associated with programmed cell death, cell growth, cell differentiation
and cell survival. KRX-0401 is currently in Phase 2 clinical development
for multiple tumor types. Keryx also has an active in-licensing and
acquisition program designed to identify and acquire additional drug
candidates. Keryx is headquartered in New York City.
Keryx Biopharmaceuticals, Inc.
|SOURCE Keryx Biopharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved